SEARCH

SEARCH BY CITATION

Literature Cited

  • Abella JV, Peschard P, Naujokas MA, Lin T, Saucier C, Urbe S, Park M. 2005. Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol Cell Biol 25: 96329645.
  • Angeloni D, Danilkovitch-Miagkova A, Miagkov A, Leonard EJ, Lerman MI. 2004. The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation. J Biol Chem 279: 37263732.
  • Bardella C, Costa B, Maggiora P, Patane S, Olivero M, Ranzani GN, De Bortoli M, Comoglio PM, Di Renzo MF. 2004. Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res 64: 51545161.
  • Bardelli A, Longati P, Gramaglia D, Basilico C, Tamagnone L, Giordano S, Ballinari D, Michieli P, Comoglio PM. 1998. Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. Proc Natl Acad Sci USA 95: 1437914383.
  • Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. 1998. Venous thromboembolism and cancer. Lancet 351: 10771080.
  • Bergstrom JD, Westermark B, Heldin NE. 2000. Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Exp Cell Res 259: 293299.
  • Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B, Stalder D, Gruber G, Liang C, Howlett AR, Candinas D, Greiner RH, Lipson KE, Zimmer Y. 2004. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 23: 53875393.
  • Bezerra JA, Han S, Danton MJ, Degen SJ. 1993. Are hepatocyte growth factor-like protein and macrophage stimulating protein the same protein? Protein Sci 2: 666668.
  • Bhowmick NA, Neilson EG, Moses HL. 2004. Stromal fibroblasts in cancer initiation and progression. Nature 432: 332337.
  • Birchmeier C, Gherardi E. 1998. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 8: 404410.
  • Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. 2003. Met, metastasis, motility and more. Nat Rev Cancer 4: 915925.
  • Boccaccio C, Ando M, Tamagnone L, Bardelli A, Michieli P, Battistini C, Comoglio PM. 1998. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391: 285288.
  • Boccaccio C, Sabatino G, Medico E, Girolami F, Follenzi A, Reato G, Sottile A, Naldini L, Comoglio PM. 2005. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 434: 396400.
  • Boon EM, van der Neut R, van de Wetering M, Clevers H, Pals ST. 2002. Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res 62: 51265128.
  • Bottaro DP, Liotta LA. 2003. Cancer: Out of air is not out of action. Nature 423: 593595.
  • Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S, McDorman K, Cattley RC, Elliott G, Zhang K, Feng X, Jia XC, Green L, Radinsky R, Kendall R. 2006. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 66: 17211729.
  • Camp ER, Liu W, Fan F, Yang A, Somcio R, Ellis LM. 2005. RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann Surg Oncol 12: 273281.
  • Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, Wang LM, Vande Woude GF. 2001. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci USA 98: 74437448.
  • Chan EL, Peace BE, Collins MH, Toney-Earley K, Waltz SE. 2005. Ron tyrosine kinase receptor regulates papilloma growth and malignant conversion in a murine model of skin carcinogenesis. Oncogene 24: 479488.
  • Chen Q, Seol DW, Carr B, Zarnegar R. 1997. Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines. Hepatology 26: 5966.
  • Chen YQ, Zhou YQ, Angeloni D, Kurtz AL, Qiang XZ, Wang MH. 2000. Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. Exp Cell Res 261: 229238.
  • Chen YQ, Zhou YQ, Fisher JH, Wang MH. 2002a. Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: Oncogenic potential of RON in vivo. Oncogene 21: 63826386.
  • Chen YQ, Zhou YQ, Fu LH, Wang D, Wang MH. 2002b. Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. Recepteur d'origine nantais. Carcinogenesis 23: 18111819.
  • Cheng HL, Liu HS, Lin YJ, Chen HH, Hsu PY, Chang TY, Ho CL, Tzai TS, Chow NH. 2005. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer 92: 19061914.
  • Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ, Cherrington JM, Mendel DB. 2003. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63: 73457355.
  • Collesi C, Santoro MM, Gaudino G, Comoglio PM. 1996. A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol 16: 55185526.
  • Comoglio PM, Boccaccio C. 1996. The HGF receptor family: Unconventional signal transducers for invasive cell growth. Genes Cells 1: 347354.
  • Conrotto P, Corso S, Gamberini S, Comoglio PM, Giordano S. 2004. Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 23: 51315137.
  • Cortesina G, Rosso P, Mola P, Ricci E, Cavalot AL, Martone T, Comoglio PM, Di Renzo F. 2000. Molecular markers study in pTNM of squamous carcinoma of the head and neck. Acta Otorhinolaryngol Ital 20: 380382.
  • Di Renzo MF, Olivero M, Katsaros D, Crepaldi T, Gaglia P, Zola P, Sismondi P, Comoglio PM. 1994. Overexpression of the Met/HGF receptor in ovarian cancer. Int J Cancer 58: 658662.
  • Di Renzo MF, Olivero M, Serini G, Orlandi F, Pilotti S, Belfiore A, Costantino A, Vigneri R, Angeli A, Pierotti MA, et al. 1995a. Overexpression of the c-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium. J Endocrinol Invest 18: 134139.
  • Di Renzo MF, Poulsom R, Olivero M, Comoglio PM, Lemoine NR. 1995b. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 55: 11291138.
  • Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA. 2007. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science 316: 10391043.
  • Ferracini R, Di Renzo MF, Scotlandi K, Baldini N, Olivero M, Lollini P, Cremona O, Campanacci M, Comoglio PM. 1995. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 10: 739749.
  • Fischer OM, Giordano S, Comoglio PM, Ullrich A. 2004. Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem 279: 2897028978.
  • Follenzi A, Bakovic S, Gual P, Stella MC, Longati P, Comoglio PM. 2000. Cross-talk between the proto-oncogenes Met and Ron. Oncogene 19: 30413049.
  • Gambarotta G, Boccaccio C, Giordano S, Ando M, Stella MC, Comoglio PM. 1996. Ets up-regulates MET transcription. Oncogene 13: 19111917.
  • Gherardi E, Gray J, Stoker M, Perryman M, Furlong R. 1989. Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement. Proc Natl Acad Sci USA 86: 58445848.
  • Giordano S, Corso S, Conrotto P, Artigiani S, Gilestro G, Barberis D, Tamagnone L, Comoglio PM. 2002. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol 4: 720724.
  • Gual P, Giordano S, Williams TA, Rocchi S, Van Obberghen E, Comoglio PM. 2000. Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene 19: 15091518.
  • Han S, Stuart LA, Degen SJ. 1991. Characterization of the DNF15S2 locus on human chromosome 3: Identification of a gene coding for four kringle domains with homology to hepatocyte growth factor. Biochemistry 30: 97689780.
  • Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100: 5770.
  • Heideman DA, van Beusechem VW, Bloemena E, Snijders PJ, Craanen ME, Offerhaus GJ, Derksen PW, de Bruin M, Witlox MA, Molenaar B, Meijer CJ, Gerritsen WR. 2004. Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK4. J Gene Med 6: 317327.
  • Huh CG, Factor VM, Sanchez A, Uchida K, Conner EA, Thorgeirsson SS. 2004. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 101: 44774482.
  • Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML. 1995. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147: 386396.
  • Ivan M, Bond JA, Prat M, Comoglio PM, Wynford-Thomas D. 1997. Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 14: 24172423.
  • Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC. 2000. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 275: 88068811.
  • Khoury H, Naujokas MA, Zuo D, Sangwan V, Frigault MM, Petkiewicz S, Dankort DL, Muller WJ, Park M. 2005. HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol Biol Cell 16: 550561.
  • Kijima Y, Hokita S, Yoshinaka H, Itoh T, Koriyama C, Eizuru Y, Akiba S, Aikou T. 2002. Amplification and overexpression of c-met gene in Epstein-Barr virus-associated gastric carcinomas. Oncology 62: 6065.
  • Kim KJ, Wang L, Su YC, Gillespie GY, Salhotra A, Lal B, Laterra J. 2006. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 12: 12921298.
  • Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. 2006. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66: 16301639.
  • Kong-Beltran M, Stamos J, Wickramasinghe D. 2004. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer cell 6: 7584.
  • Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E. 1992. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 189: 227232.
  • Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, Schmidt L, Zbar B, Vande Woude GF. 2000. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19: 49474953.
  • Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, Gibbs JB, Pan BS. 2007. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 67: 20812088.
  • Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG, Salgia R. 2005. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65: 14791488.
  • Maggiora P, Marchio S, Stella MC, Giai M, Belfiore A, De Bortoli M, Di Renzo MF, Costantino A, Sismondi P, Comoglio PM. 1998. Overexpression of the RON gene in human breast carcinoma. Oncogene 16: 29272933.
  • Maggiora P, Lorenzato A, Fracchioli S, Costa B, Castagnaro M, Arisio R, Katsaros D, Massobrio M, Comoglio PM, Flavia Di Renzo M. 2003. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res 288: 382389.
  • Maina F, Casagranda F, Audero E, Simeone A, Comoglio PM, Klein R, Ponzetto C. 1996. Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. Cell 87: 531542.
  • Maina F, Pante G, Helmbacher F, Andres R, Porthin A, Davies AM, Ponzetto C, Klein R. 2001. Coupling Met to specific pathways results in distinct developmental outcomes. Mol Cell 7: 12931306.
  • Maroun CR, Naujokas MA, Holgado-Madruga M, Wong AJ, Park M. 2000. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol 20: 85138525.
  • Matsumoto K, Nakamura T. 2003. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 94: 321327.
  • Mazzone M, Basilico C, Cavassa S, Pennacchietti S, Risio M, Naldini L, Comoglio PM, Michieli P. 2004. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest 114: 14181432.
  • Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, Comoglio PM. 2004. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6: 6173.
  • Miller CT, Lin L, Casper AM, Lim J, Thomas DG, Orringer MB, Chang AC, Chambers AF, Giordano TJ, Glover TW, Beer DG. 2006. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 25: 409418.
  • Montesano R, Matsumoto K, Nakamura T, Orci L. 1991. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 67: 901908.
  • Morello S, Olivero M, Aimetti M, Bernardi M, Berrone S, Di Renzo MF, Giordano S. 2001. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas. J Cell Physiol 189: 285290.
  • Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A. 2005. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 6: 279286.
  • Morotti A, Mila S, Accornero P, Tagliabue E, Ponzetto C. 2002. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 21: 48854893.
  • Muraoka RS, Sun WY, Colbert MC, Waltz SE, Witte DP, Degen JL, Friezner Degen SJ. 1999. The Ron/STK receptor tyrosine kinase is essential for peri-implantation development in the mouse. J Clin Invest 103: 12771285.
  • Nakamura T, Teramoto H, Ichihara A. 1986. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci USA 83: 64896493.
  • Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H. 2000. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 106: 15111519.
  • Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A. 2005. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 206: 356365.
  • Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, Narsimhan RP, Hartmann G, Zarnegar R, Michalopoulos GK, et al. 1991. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. Embo J 10: 28672878.
  • Natali PG, Prat M, Nicotra MR, Bigotti A, Olivero M, Comoglio PM, Di Renzo MF. 1996. Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer 69: 212217.
  • Okino T, Egami H, Ohmachi H, Takai E, Tamori Y, Nakagawa A, Nakano S, Sakamoto O, Suda T, Ogawa M. 2001. Immunohistochemical analysis of distribution of RON receptor tyrosine kinase in human digestive organs. Dig Dis Sci 46: 424429.
  • Olivero M, Rizzo M, Madeddu R, Casadio C, Pennacchietti S, Nicotra MR, Prat M, Maggi G, Arena N, Natali PG, Comoglio PM, Di Renzo MF. 1996. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 74: 18621868.
  • Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. 2002. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 16: 30743086.
  • O'Toole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P, Covino N, Bassi R, Prewett M, Gottfredsen KJ, Thobe MN, Cheng Y, Li Y, Hicklin DJ, Zhu Z, Waltz SE, Hayman MJ, Ludwig DL, Pereira DS. 2006. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res 66: 91629170.
  • Peace BE, Hughes MJ, Degen SJ, Waltz SE. 2001. Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis. Oncogene 20: 61426151.
  • Pelicci G, Giordano S, Zhen Z, Salcini AE, Lanfrancone L, Bardelli A, Panayotou G, Waterfield MD, Ponzetto C, Pelicci PG, et al. 1995. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene 10: 16311638.
  • Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. 2003. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347361.
  • Peschard P, Fournier TM, Lamorte L, Naujokas MA, Band H, Langdon WY, Park M. 2001. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell 8: 9951004.
  • Petrelli A, Circosta P, Granziero L, Mazzone M, Pisacane A, Fenoglio S, Comoglio PM, Giordano S. 2006. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci USA 103: 50905095.
  • Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, Graziani A, Panayotou G, Comoglio PM. 1994. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77: 261271.
  • Ponzetto C, Zhen Z, Audero E, Maina F, Bardelli A, Basile ML, Giordano S, Narsimhan R, Comoglio P. 1996. Specific uncoupling of GRB2 from the Met receptor. Differential effects on transformation and motility. J Biol Chem 271: 1411914123.
  • Porte H, Triboulet JP, Kotelevets L, Carrat F, Prevot S, Nordlinger B, DiGioia Y, Wurtz A, Comoglio P, Gespach C, Chastre E. 1998. Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: Implications for prognosis. Clin Cancer Res 4: 13751382.
  • Rampino T, Gregorini M, Soccio G, Maggio M, Rosso R, Malvezzi P, Collesi C, Dal Canton A. 2003. The Ron proto-oncogene product is a phenotypic marker of renal oncocytoma. Am J Surg Pathol 27: 779785.
  • Rickles FR, Levine MN. 2001. Epidemiology of thrombosis in cancer. Acta Haematol 106: 612.
  • Rong S, Segal S, Anver M, Resau JH, Vande Woude GF. 1994. Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci USA 91: 47314735.
  • Royal I, Fournier TM, Park M. 1997. Differential requirement of Grb2 and PI3-kinase in HGF/SF-induced cell motility and tubulogenesis. J Cell Physiol 173: 196201.
  • Sachs M, Brohmann H, Zechner D, Muller T, Hulsken J, Walther I, Schaeper U, Birchmeier C, Birchmeier W. 2000. Essential role of Gab1 for signaling by the c-Met receptor in vivo. J Cell Biol 150: 13751384.
  • Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B. 1997a. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16: 6873.
  • Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B. 1997b. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16: 6873.
  • Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, Vande Woude GF. 2004. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res 64: 79627970.
  • Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, Haber DA. 2006. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 103: 23162321.
  • Stoker M, Gherardi E, Perryman M, Gray J. 1987. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327: 239242.
  • Tagliabue E, Centis F, Campiglio M, Mastroianni A, Martignone S, Pellegrini R, Casalini P, Lanzi C, Menard S, Colnaghi MI. 1991. Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification. Int J Cancer 47: 933937.
  • Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, Aaronson SA, Merlino G. 1997. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 94: 701706.
  • Takeo S, Arai H, Kusano N, Harada T, Furuya T, Kawauchi S, Oga A, Hirano T, Yoshida T, Okita K, Sasaki K. 2001. Examination of oncogene amplification by genomic DNA microarray in hepatocellular carcinomas: Comparison with comparative genomic hybridization analysis. Cancer Genet Cytogenet 130: 127132.
  • Tamagnone L, Comoglio PM. 1997. Control of invasive growth by hepatocyte growth factor (HGF) and related scatter factors. Cytokine Growth Factor Rev 8: 129142.
  • Tamagnone L, Artigiani S, Chen H, He Z, Ming GI, Song H, Chedotal A, Winberg ML, Goodman CS, Poo M, Tessier-Lavigne M, Comoglio PM. 1999. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 99: 7180.
  • Taniguchi K, Yonemura Y, Nojima N, Hirono Y, Fushida S, Fujimura T, Miwa K, Endo Y, Yamamoto H, Watanabe H. 1998. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer 82: 21122122.
  • Taulli R, Scuoppo C, Bersani F, Accornero P, Forni PE, Miretti S, Grinza A, Allegra P, Schmitt-Ney M, Crepaldi T, Ponzetto C. 2006. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 66: 47424749.
  • Trusolino L, Comoglio PM. 2002. Scatter-factor and semaphorin receptors: Cell signalling for invasive growth. Nat Rev Cancer 2: 289300.
  • Trusolino L, Bertotti A, Comoglio PM. 2001. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 107: 643654.
  • van der Voort R, Taher TE, Wielenga VJ, Spaargaren M, Prevo R, Smit L, David G, Hartmann G, Gherardi E, Pals ST. 1999. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J Biol Chem 274: 64996506.
  • Vogelstein B, Kinzler KW. 2004. Cancer genes and the pathways they control. Nat Med 10: 789799.
  • Waltz SE, Eaton L, Toney-Earley K, Hess KA, Peace BE, Ihlendorf JR, Wang MH, Kaestner KH, Degen SJ. 2001. Ron-mediated cytoplasmic signaling is dispensable for viability but is required to limit inflammatory responses. J Clin Invest 108: 567576.
  • Wang MH, Gonias SL, Skeel A, Wolf BB, Yoshimura T, Leonard EJ. 1994. Proteolytic activation of single-chain precursor macrophage-stimulating protein by nerve growth factor-gamma and epidermal growth factor-binding protein, members of the kallikrein family. J Biol Chem 269: 1380613810.
  • Wang X, DeFrances MC, Dai Y, Pediaditakis P, Johnson C, Bell A, Michalopoulos GK, Zarnegar R. 2002. A mechanism of cell survival: Sequestration of Fas by the HGF receptor Met. Mol Cell 9: 411421.
  • Wang MH, Wang D, Chen YQ. 2003. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis 24: 12911300.
  • Weidner KM, Di Cesare S, Sachs M, Brinkmann V, Behrens J, Birchmeier W. 1996. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 384: 173176.
  • Weinstein IB. 2002. Cancer. Addiction to oncogenes—The Achilles heal of cancer. Science 297: 6364.
  • Wickramasinghe D, Kong-Beltran M. 2005. Met activation and receptor dimerization in cancer: A role for the Sema domain. Cell Cycle 4: 683685.
  • Willett CG, Wang MH, Emanuel RL, Graham SA, Smith DI, Shridhar V, Sugarbaker DJ, Sunday ME. 1998. Macrophage-stimulating protein and its receptor in non-small-cell lung tumors: Induction of receptor tyrosine phosphorylation and cell migration. Am J Respir Cell Mol Biol 18: 489496.
  • Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, Testa JR. 2001. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 98: 247252.
  • Xu XM, Wang D, Shen Q, Chen YQ, Wang MH. 2004. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. Oncogene 23: 84648474.
  • Zanetti A, Stoppacciaro A, Marzullo A, Ciabatta M, Fazioli F, Prat M, Comoglio PM, Baroni CD, Ruco LP. 1998. Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid. J Pathol 186: 287291.
  • Zhou YQ, He C, Chen YQ, Wang D, Wang MH. 2003. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: Generation of different splicing RON variants and their oncogenic potential. Oncogene 22: 186197.